Should we consider the cost-effectiveness of the different therapies when applying the recommendations on phosphorus-chelating agents?;¿Debemos considerar el costo-efectividad de los distintos tratamientos al aplicar las recomendaciones sobre los captores (quelantes) de fósforo?

Nefrologia

Volumn 28, Issue 2, 2008, Pages 129-134

  Martín De Francisco, Ángel Luis ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; PHOSPHATE;

CHRONIC KIDNEY FAILURE; COST BENEFIT ANALYSIS; ECONOMICS; EDITORIAL; HUMAN; HYPERPHOSPHATEMIA; METABOLISM; PRACTICE GUIDELINE;

CHELATING AGENTS; COST-BENEFIT ANALYSIS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; PHOSPHATES; PRACTICE GUIDELINES AS TOPIC;

EID: 51149100779     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (39)

1. Clarkson EM, Luck VA, Hynson WV, Bailey RR, Eastwood JB, Woodhead JS, Clements VR, O'Riordan JL, De Wardener HE. The effect of aluminum hydroxide on calcium, phosphorus and aluminum balances, the serum parathyroid hormone concentrations and the aluminum content of bone in patients with chronic renal failure. Clin Sci 1972; 43: 519-531.
2. Alfrey AC, Mishell JM, Burks J, Contiguglia SR, Rudolph H, Lewin E, Holmes JH. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972; 18: 257-261.
3. Alfrey AC, Legendre GR, Kaehny WD. The dialysis encephalopathy syndrome: possible aluminum intoxication. N Engl J Med 1976; 294: 184-188.
4. Pierides AM, Edwards WG, Cullum UX, McCall JT, Ellis HA. Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980; 8: 115-124.
5. Sechet A, Hardy P, Hottelart C, Rasombololona M, Abighanem O, Oualim Z, Brazier M, Achard JM, Pruna A, Moriniere P, Fournier A. Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis. Artif Organs 1998; 22: 564-568.
6. Mai M, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36: 690-695.
7. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991; 17: 544-550.
8. Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, Von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991; 6: 170-175.
9. Goodman, WG, Goldin, J, Kuizon, BD y cols. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478;
10. Block, GA, Port, FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226.
11. Friedman E. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 2006; 1 (4): 704-9.
12. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006; 1 (4): 697-703.
13. Deuber HJ. Nieren-und Hochdruckkrankheiten 2004; 33 (8): 403-8;
14. Burke SL, Slatopolsky EA, Goldberg DI. Renagel, a novel calcium-and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12: 1640-1644.
15. Chertow GM, Burke SK, Dillon MA, Slatopolsky E; for the RenaGel Study Group: long-term effects of sevelamer hydrochloride on the calcium phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914.
16. Chertow GM, Burke SK, Lazarus JM y cols. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66.
17. Goldberg DI, Dillon MA, Slatopolsky EA y cols. Effect of RenaGel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13: 2303.
18. Slatopolsky EA, Burke SK, Dillon MA, and the RenaGel study group. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299.
19. Chertow GM, Dillon M, Burke SK y cols. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium -Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51: 18.
20. Bleyer AJ, Burke SK, Dillon M y cols. A comparison of the calcium-free phosphate binder Sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694.
21. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245.
22. Sadek T, Mazouz H, Bahloul H y cols. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 2003; 18: 582.
23. Ogata H, Koiwa F, Shishido K, Kinugasa E. Combination therapy with Sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial 2005; 9: 11.
24. Fischer D, Cline K, Plone MA, y cols. Results of a randomized crossover study comparing once-daily and thrice-daily Sevelamer dosing. Am J Kidney Dis 2006; 48: 437.
25. Ferramosca E, Burke S, Chasan-Taber S y cols. Potential antiatherogenic and anti-inflammatory properties of Sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820.
26. Qunibi WY, Hootkins RE, McDowell LL y cols. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65: 1914.
27. Suki W, Zabaneh R, Cangiano J, y cols. A prospective randomized trial assessing the impact on outcomes of Sevelamer in dialysis patients. The DCOR trial. Nephrol Dial Transplant 2006; 21 (Supl. 4): 145.
28. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B; for the Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of Sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22 (10): 2856-66.
29. Palmer SC, Craig JC, Strippoli GF. Sevelamer: a promising but unproven drug. Nephrol Dial Transplant 2007; 22 (10): 2742-5.
30. Damment SJP, Webster I. The pharmacology of lanthanum carbonate: a new non-aluminum-, non-calcium phosphate binder [Abstract]. J Am Soc Nephrol 2003; 14: 204A.
31. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42: 96.
32. Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004; 19: 1902.
33. Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004; 62: 193.
34. Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 2004; 13: 403.
35. Hutchison AJ, Maes B, Vanwalleghem J y cols. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100: c8.
36. Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, De Broe ME, D'Haese PC. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004; 15 (8): 2219-28.
37. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005; 68 (6): 2809-13.
38. Persy VP, Behets GJ, Bervoets AR, De Broe ME, D'Haese PC. Lanthanum: a safe phosphate binder. Semin Dial 2006; 19 (3): 195-9.
39. Lorenzo V, Martín-Malo A, Pérez-García R, Torregrosa JV, Vega N, De Francisco AL, Cases A. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant 2006; 21 (2): 459-65.